Evaluation of Negative Pressure Wound Therapy in the Treatment of DFUs Incl. Post Amputation Wounds.
NCT ID: NCT01011387
Last Updated: 2012-03-21
Study Results
Outcome measurements, participant flow, baseline characteristics, and adverse events have been published for this study.
View full resultsBasic Information
Get a concise snapshot of the trial, including recruitment status, study phase, enrollment targets, and key timeline milestones.
COMPLETED
NA
16 participants
INTERVENTIONAL
2010-01-31
2010-07-31
Brief Summary
Review the sponsor-provided synopsis that highlights what the study is about and why it is being conducted.
* To assess wound healing and granulation tissue formation when using the NPWT system
Secondary objectives
* To investigate the pain level at dressing removal
* To visually check exudate removal
* To investigate the ease of use for the subject and care giver when using the NPWT system
Related Clinical Trials
Explore similar clinical trials based on study characteristics and research focus.
Diabetes Related Foot Ulcers with Negative Pressure Wound Therapy
NCT06721754
Negative Pressure Wound Therapy in the Management of Diabetic Foot Ulcers
NCT04093635
Treatment Study of Negative Pressure Wound Therapy for Diabetic Foot Wounds
NCT01480362
Evaluating Plantar Foot Pressure in a Novel Diabetic Offloading Device
NCT04336176
A Prospective, Open, Non-controlled Clinical Investigation to Evaluate a New Negative Pressure Wound Therapy (NPWT) System to be Used in the Treatment of Acute Non-infected Wounds and Post Surgical Infected Wounds
NCT01195896
Detailed Description
Dive into the extended narrative that explains the scientific background, objectives, and procedures in greater depth.
Wounds to be treated under this protocol should be Diabetic foot ulcers (DFUs) or post amputation wounds associated with diabetes in hospitalized subjects or subjects treated at home. One ulcer or post amputation wound per subject will be treated for a maximum duration of 4 weeks. All subjects will receive negative pressure treatment with the NPWT system, -120 mm Hg.
In total, 10-15 subjects at two sites will be enrolled provided that they fulfill all the inclusion criteria and none of the exclusion criteria and have signed and dated a written informed consent.
The subjects will be consecutively allocated to a specific subject identification code and the recruitment will be competitive.
The primary variable wound healing and granulation tissue formation will be assessed by digital planimeter, digital photography and visual estimation.
Pain level and subject/investigator convenience will be assessed by convenience surveys.
An evaluable subject is defined as a subject completing the investigation with 4 weeks of treatment, a subject healed before 4 weeks of treatment or if the investigator judge that the wound has adequately responded on NPWT before 4 weeks and that continued treatment can be made with alternative treatment.
Conditions
See the medical conditions and disease areas that this research is targeting or investigating.
Study Design
Understand how the trial is structured, including allocation methods, masking strategies, primary purpose, and other design elements.
NA
SINGLE_GROUP
TREATMENT
NONE
Study Groups
Review each arm or cohort in the study, along with the interventions and objectives associated with them.
NPWT system
Negative pressure wound therapy
NPWT System
Dressing change 3 times per week
NPWT system
3 dressing changes/week for maximum 4 weeks.
Interventions
Learn about the drugs, procedures, or behavioral strategies being tested and how they are applied within this trial.
NPWT System
Dressing change 3 times per week
NPWT system
3 dressing changes/week for maximum 4 weeks.
Eligibility Criteria
Check the participation requirements, including inclusion and exclusion rules, age limits, and whether healthy volunteers are accepted.
Inclusion Criteria
2. 1 cm2 ≤ Wound size ≤ 200 cm2
3. Male or female, 18 years and above
4. Signed Informed Consent Form
5. Subject understands the written subject Information
Exclusion Criteria
2. Dry wounds
3. Critical ischemia (for wound healing) according to investigator's judgement
4. Malignancy in the wound and/or wound margin
5. Target ulcer previous not successfully treated with NPWT within 48 hours
6. Poorly controlled diabetes according to investigators judgement.
7. Osteomyelitis which has been left untreated
8. Infection which has been left untreated
9. Unexplored fistula
10. \> 10% surface area necrotic tissue with eschar present after debridement
11. High risk for bleeding complications
12. Exposed major blood vessels, organs or nerves
13. Current or within 3 months treatment with chemotherapy or irradiation
14. Known hypersensitivity to the dressing material
15. Expected technically impossible to seal the film to maintain a vacuum for treatment
16. Expected non compliance with the Clinical Investigation Plan
17. Pregnancy
18. Subjects not suitable for the investigation according to the investigator's judgement
19. Subjects previously included in this investigation
20. Subjects included in other ongoing clinical investigation at present or during the past 30 days
18 Years
ALL
No
Sponsors
Meet the organizations funding or collaborating on the study and learn about their roles.
Molnlycke Health Care AB
INDUSTRY
Responsible Party
Identify the individual or organization who holds primary responsibility for the study information submitted to regulators.
Principal Investigators
Learn about the lead researchers overseeing the trial and their institutional affiliations.
Gerard Stansby, MD, Prof.
Role: PRINCIPAL_INVESTIGATOR
Freeman Hospital, Newcastle upon tyne
Locations
Explore where the study is taking place and check the recruitment status at each participating site.
Freeman Hospital
Newcastle upon Tyne, , United Kingdom
Norfolk & Norwich University Hospital
Norfolk,, , United Kingdom
Countries
Review the countries where the study has at least one active or historical site.
Other Identifiers
Review additional registry numbers or institutional identifiers associated with this trial.
NPWT 01
Identifier Type: -
Identifier Source: org_study_id
More Related Trials
Additional clinical trials that may be relevant based on similarity analysis.